Related Experiment Video
Updated: Aug 5, 2026
03:36
Development of Compendium for Esophageal Squamous Cell Carcinoma
Published on: April 12, 2024
Esophageal and Gastric Cancers
Anushna Sunila Babu1, Mohammad Umar1, Abass Alavi2
1Department of Nuclear Medicine, All India Institute of Medical Sciences, Ansari Nagar East, New Delhi, 110029, Delhi, India.
PET Clinics
|August 1, 2026
Summary
Fluorine-18 fluorodeoxyglucose (18F-FDG) PET/CT improves cancer staging and treatment assessment for esophageal and gastric cancers. This imaging technique is vital for detecting metastases and guiding therapy, especially for specific cancer subtypes.
Area of Science:
- Oncology
- Nuclear Medicine
- Radiology
Background:
- Esophageal and gastric cancers have high mortality rates often linked to late diagnosis.
- Accurate staging and response assessment are crucial for effective cancer management.
Purpose of the Study:
- To evaluate the role of 18F-FDG PET/CT in staging and response assessment of esophageal and gastric cancers.
- To highlight the clinical utility of integrated metabolic and anatomic imaging in oncology.
Main Methods:
- Utilized 18F-FDG PET/CT, combining metabolic (PET) and anatomic (CT) imaging.
- Assessed the diagnostic performance in detecting occult metastases and evaluating treatment response.
- Examined efficacy across different subtypes of gastric adenocarcinoma and esophageal cancer.
Main Results:
- 18F-FDG PET/CT is pivotal for detecting occult metastases and assessing early treatment response.
- The technique shows high effectiveness in esophageal cancer and intestinal-type gastric adenocarcinoma.
- Sensitivity is limited in diffuse and mucinous gastric cancer subtypes.
- PET/CT aids in radiotherapy planning and differentiating recurrence from post-treatment changes.
Conclusions:
- 18F-FDG PET/CT is an essential tool for improving patient outcomes in esophageal and gastric cancers.
- It enhances diagnostic accuracy, treatment guidance, and monitoring of therapeutic effects.
- Understanding subtype-specific performance is key for optimal application.
Related Concept Videos
01:30Esophageal Strictures-I: Introduction
Esophageal strictures involve abnormal narrowing or tightening of the esophagus. They vary in length and severity, ranging from mild constriction to complete obstruction, and are classified as benign (noncancerous) or malignant (cancerous).
Etiology
The primary cause of esophageal strictures is long-standing gastroesophageal reflux disease (GERD), accounting for about 70 to 80% of adult cases. Chronic acid reflux can lead to injury and scarring of the esophageal lining, culminating in...
Etiology
The primary cause of esophageal strictures is long-standing gastroesophageal reflux disease (GERD), accounting for about 70 to 80% of adult cases. Chronic acid reflux can lead to injury and scarring of the esophageal lining, culminating in...
01:21Barrett Esophagus-I: Introduction
Barrett's esophagus is a medical condition where the esophageal mucosa is significantly damaged by stomach acid or other digestive fluids, often due to long-term exposure associated with gastroesophageal reflux disease (GERD). In GERD, a weakened or abnormally relaxed lower esophageal sphincter allows stomach acid to flow persistently into the esophagus.
This constant acid exposure transforms the esophagus's pink mucosal lining (stratified squamous epithelium) into a type of lining more similar...
This constant acid exposure transforms the esophagus's pink mucosal lining (stratified squamous epithelium) into a type of lining more similar...
01:27Esophageal Achalasia
Esophageal achalasia is a chronic neurogenic disorder characterized by impaired relaxation of the lower esophageal sphincter (LES) and absent or ineffective peristalsis in the distal esophagus. This leads to a functional obstruction without a physical blockage, despite significant disruption of esophageal motility.EtiologyAchalasia is caused by degeneration of the myenteric (Auerbach's) plexus, specifically the loss of inhibitory ganglion cells that produce vasoactive intestinal peptide (VIP)...
01:21Barrett Esophagus-II: Clinical Manifestations and Management
Individuals with Barrett's esophagus are often asymptomatic, but they may experience symptoms commonly associated with GERD, such as heartburn and acid regurgitation. Additional symptoms can include difficulty swallowing, chest pain, unintentional weight loss, blood in the stool (which may appear black, tarry, or bloody), and episodes of vomiting.
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure entails...
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure entails...
01:24Esophageal Varices-I: Introduction
Esophageal varices are dilated, tortuous veins which are found mainly in the submucosa of the lower esophagus but which may also appear higher up or extend into the stomach. They develop due to increased pressure in the portal venous system, often as a result of liver cirrhosis. This condition scars and damages the liver, impeding normal blood flow through the portal vein. To compensate, blood seeks alternative pathways, forming fragile new vessels (varices) in the esophagus and stomach. These...
01:11Pyloric Obstruction
Pyloric obstruction, also referred to as gastric outlet obstruction, is a condition characterized by narrowing or blockage at the pylorus—the muscular valve regulating the flow of stomach contents into the duodenum. When this passage becomes impaired, the stomach cannot effectively empty its contents into the small intestine. This disruption leads to a range of gastrointestinal symptoms, including early satiety, bloating, epigastric pain, postprandial nausea, persistent vomiting, and...